Azimuth Pharma Limited - Limited company - abbreviated - 11.0.0

Azimuth Pharma Limited - Limited company - abbreviated - 11.0.0


07916512 G Smith M Stanton S Bennett 1.4.13 31.3.14 31.3.14 Company accounts Private Limited Company FY true false true false true false false Ordinary 0.01000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure079165122013-03-31079165122014-03-31079165122013-04-012014-03-31079165122012-01-08079165122012-01-092013-03-31079165122013-03-3107916512ns12:England2013-04-012014-03-3107916512ns14:PoundSterling2013-04-012014-03-3107916512ns7:Director12013-04-012014-03-3107916512ns7:Director22013-04-012014-03-3107916512ns7:Director32013-04-012014-03-3107916512ns7:OrdinaryShareClass12013-04-012014-03-3107916512ns7:RegisteredOffice2013-04-012014-03-3107916512ns7:EntityAccountantsOrAuditors2013-04-012014-03-3107916512ns5:FixedAssetInvestmentsOtherThanLoans2014-03-3107916512ns5:FixedAssetInvestmentsOtherThanLoans2013-03-3107916512ns5:Subsidiary12013-04-012014-03-3107916512ns5:Subsidiary12012-01-092013-03-3107916512ns5:Subsidiary22013-04-012014-03-3107916512ns7:OrdinaryShareClass12014-03-3107916512ns7:OrdinaryShareClass12013-03-31
REGISTERED NUMBER: 07916512 (England and Wales)















Abbreviated Unaudited Accounts for the Year Ended 31 March 2014

for

Azimuth Pharma Limited

Azimuth Pharma Limited (Registered number: 07916512)






Contents of the Abbreviated Accounts
for the Year Ended 31 March 2014




Page

Company Information 1

Abbreviated Balance Sheet 2

Notes to the Abbreviated Accounts 3

Chartered Accountants' Report 4

Azimuth Pharma Limited

Company Information
for the Year Ended 31 March 2014







DIRECTORS: S Bennett
G Smith
M Stanton





REGISTERED OFFICE: 22 Great James Street
London
WC1N 3ES





REGISTERED NUMBER: 07916512 (England and Wales)





ACCOUNTANTS: Caroline Gibbons ACA CTA
26 Eastwick Drive
Great Bookham
Leatherhead
Surrey
KT23 3PR

Azimuth Pharma Limited (Registered number: 07916512)

Abbreviated Balance Sheet
31 March 2014

31.3.14 31.3.13
Notes £    £    £    £   
FIXED ASSETS
Investments 2 526,637 526,637

CURRENT ASSETS
Cash at bank 3,376 4,563
NET CURRENT ASSETS 3,376 4,563
TOTAL ASSETS LESS CURRENT
LIABILITIES

530,013

531,200

CREDITORS
Amounts falling due after more than one
year

525,424

526,737
NET ASSETS 4,589 4,463

CAPITAL AND RESERVES
Called up share capital 3 10 10
Profit and loss account 4,579 4,453
SHAREHOLDERS' FUNDS 4,589 4,463

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2014.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2014 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies
Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of
each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections
394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial
statements, so far as applicable to the company.

The abbreviated accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.


The financial statements were approved by the Board of Directors on 21 November 2014 and were signed on its behalf
by:



G Smith - Director M Stanton - Director



S Bennett - Director


Azimuth Pharma Limited (Registered number: 07916512)

Notes to the Abbreviated Accounts
for the Year Ended 31 March 2014

1. ACCOUNTING POLICIES

Accounting convention
The financial statements have been prepared under the historical cost convention and in accordance with the
Financial Reporting Standard for Smaller Entities (effective April 2008).

Preparation of consolidated financial statements
The financial statements contain information about Azimuth Pharma Limited as an individual company and do
not contain consolidated financial information as the parent of a group. The company has taken the option under
Section 398 of the Companies Act 2006 not to prepare consolidated financial statements.

2. FIXED ASSET INVESTMENTS
Investments
other
than
loans
£   
COST
At 1 April 2013
and 31 March 2014 526,637
NET BOOK VALUE
At 31 March 2014 526,637
At 31 March 2013 526,637

The company's investments at the balance sheet date in the share capital of companies include the following:

Fortis Pharma Consulting Ltd
Nature of business: Marketing in the pharmaceutical industry
%
Class of shares: holding
Ordinary 100.00
31.3.14 31.3.13
£    £   
Aggregate capital and reserves 700,917 732,926
Profit for the year/period 144,519 153,652

Sapience Medical Education Ltd
Nature of business: Dormant
%
Class of shares: holding
Ordinary 100.00

3. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.3.14 31.3.13
value: £    £   
100 Ordinary .01 10 10

Chartered Accountants' Report to the Board of Directors
on the Unaudited Financial Statements of
Azimuth Pharma Limited

The following reproduces the text of the report prepared for the directors in respect of the company's annual
unaudited financial statements, from which the unaudited abbreviated accounts (set out on pages two to three)
have been prepared.

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the
financial statements of Azimuth Pharma Limited for the year ended 31 March 2014 which comprise the Profit and Loss
Account, the Balance Sheet and the related notes from the company's accounting records and from information and
explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject
to its ethical and other professional requirements which are detailed at icaew.com/membershandbook.

This report is made solely to the Board of Directors of Azimuth Pharma Limited, as a body, in accordance with our
terms of engagement. Our work has been undertaken solely to prepare for your approval the financial statements of
Azimuth Pharma Limited and state those matters that we have agreed to state to the Board of Directors of Azimuth
Pharma Limited, as a body, in this report in accordance with AAF 2/10 as detailed at icaew.com/compilation. To the
fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its
Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Azimuth Pharma Limited has kept adequate accounting records and to prepare statutory
financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Azimuth
Pharma Limited. You consider that Azimuth Pharma Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Azimuth Pharma Limited.
For this reason, we have not verified the accuracy or completeness of the accounting records or information and
explanations you have given to us and we do not, therefore, express any opinion on the statutory financial statements.






Caroline Gibbons ACA CTA
26 Eastwick Drive
Great Bookham
Leatherhead
Surrey
KT23 3PR


21 November 2014